Magnolia Capital Advisors’s DiaMedica Therapeutics DMAC Stock Holding History

Magnolia Capital Advisors’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$524K	Hold	77,405	–	–	0.1%	199
2025 Q4	$616K	Buy	77,405 +67,405	+674%	+$504K	0.13%	155
2025 Q3	$68.7K	Hold	10,000	–	–	0.02%	232
2025 Q2	$39K	Hold	10,000	–	–	0.01%	240
2025 Q1	$37.9K	Sell	10,000 -160	-2%	-$915	0.01%	225
2024 Q4	$55.2K	Buy	10,160 +160	+2%	+$755	0.01%	228
2024 Q3	$41.9K	Hold	10,000	–	–	0.02%	140
2024 Q2	$29.5K	Buy	+10,000	New	+$27.4K	0.02%	121

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Magnolia Capital Advisors's DMAC Position: Q1 2026 in Review

Magnolia Capital Advisors held its DiaMedica Therapeutics (DMAC) position steady in Q1 2026 at 77,405 shares worth $524K. The position accounts for 0.1% of the portfolio, ranked #199.

Magnolia Capital Advisors first reported a position in DMAC in Q2 2024 and has held it in 8 quarters since. The position peaked at $616K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

Magnolia Capital Advisors held 77,405 shares of DiaMedica Therapeutics worth $524K as of Q1 2026.
Magnolia Capital Advisors left its DiaMedica Therapeutics share count unchanged in Q1 2026.
DiaMedica Therapeutics made up 0.1% of Magnolia Capital Advisors's portfolio in Q1 2026, its #199 holding.
Magnolia Capital Advisors first reported a position in DiaMedica Therapeutics in Q2 2024 and has held it in 8 quarters since.
Magnolia Capital Advisors's DiaMedica Therapeutics position peaked at $616K in Q4 2025.
98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Magnolia Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.